WO2019037757A1 - 一种包含美洛昔康的可注射的药物组合物及其制备方法 - Google Patents

一种包含美洛昔康的可注射的药物组合物及其制备方法 Download PDF

Info

Publication number
WO2019037757A1
WO2019037757A1 PCT/CN2018/101924 CN2018101924W WO2019037757A1 WO 2019037757 A1 WO2019037757 A1 WO 2019037757A1 CN 2018101924 W CN2018101924 W CN 2018101924W WO 2019037757 A1 WO2019037757 A1 WO 2019037757A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
meloxicam
surface stabilizer
composition according
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/101924
Other languages
English (en)
French (fr)
Inventor
孙琼
史海贤
刘凯
刘廷
侍从建
陈新新
柴夫娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to KR1020207004076A priority Critical patent/KR20200046018A/ko
Priority to AU2018321744A priority patent/AU2018321744A1/en
Priority to JP2020508401A priority patent/JP2020531424A/ja
Priority to US16/638,842 priority patent/US20200360268A1/en
Priority to EP18849101.3A priority patent/EP3673897A4/en
Priority to CA3070251A priority patent/CA3070251A1/en
Priority to BR112020001907-0A priority patent/BR112020001907A2/pt
Priority to RU2020108079A priority patent/RU2020108079A/ru
Priority to CN202111036633.4A priority patent/CN113925830B/zh
Priority to CN201880004385.5A priority patent/CN109963555B/zh
Publication of WO2019037757A1 publication Critical patent/WO2019037757A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the present invention relates to the field of pharmaceutical preparations, and in particular to an injectable pharmaceutical composition comprising meloxicam and a process for the preparation thereof.
  • Meloxicam is a highly effective non-steroidal anti-inflammatory drug for the treatment of rheumatoid arthritis, osteoarthritis and post-operative pain.
  • Meloxicam selectively inhibits COX-2 isoenzymes, has potent anti-inflammatory and analgesic effects, and has a low gastrointestinal response.
  • the currently marketed varieties include oral dosage forms such as meloxicam tablets and meloxicam capsules, and intramuscular injections of meloxicam injection. Disadvantages of oral dosage forms are: due to poor wettability of the raw materials and low solubility (pH 1.2 and 4.0, solubility is only 0.6 ⁇ g/mL), the absorption is slow and cannot be used for acute rheumatism, arthritis and pain. Although intramuscular injection improves the absorption of the drug, the rate of absorption is still limited by the solubility of the drug substance, and it also causes local tissue pain. Therefore, solubilization is the key to improving the pharmacokinetic parameters of meloxicam.
  • meloxicam nanocrystals have obvious clinical advantages, they do not require carrier materials, only a small amount of surface Stabilizers, without the toxicity problems caused by excipients (such as hemolysis, allergic reactions, etc.), are not subject to the encapsulation rate and drug loading, and can meet the needs of high-dose, high-concentration preparations.
  • the advantages of nanocrystals are also reflected in the following aspects:
  • Nanocrystalline technology significantly improved the bioavailability of meloxicam, with AUC and Cmax being 1.2 times and 1.3 times, respectively, for isodose tablets.
  • meloxicam intravenous injection can avoid serious adverse reactions such as respiratory depression, nausea and vomiting, excessive sedation, and mental dependence.
  • meloxicam as a COX-2 selective inhibitor, has fewer adverse effects than other non-steroidal anti-inflammatory drugs.
  • Nanocrystals are nano-sized suspensions of solid particles. They are thermodynamically unstable systems that are prone to settling and render the injection unusable.
  • CN101175481A discloses the addition of at least one surface stabilizer to an injectable tacrolimus nanoparticle formulation such that the composition substantially retains nanoparticle size when dispersed in a bio-related medium, with little aggregation.
  • US9345665 discloses a meloxicam nanoparticle injection comprising nanoscale meloxicam granules, a surface surface stabilizer, and a sugar or buffer, etc., which can alleviate the sedimentation generated in the nanoparticle injection, but the injection The solution will still have some insoluble particles after being placed for 1 to 3 months, which will affect the stability of the injection.
  • the invention provides a stable meloxicam nanoparticle injection, in particular, the invention provides an injectable pharmaceutical composition comprising meloxicam nanoparticles and a surface stabilizer, The pharmaceutical composition also contains a sedimentation inhibitor.
  • the sedimentation inhibitor may be selected from a polyhydric alcohol or a high molecular polymer, such as glycerin, propylene glycol, polyethylene glycol (for example, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, polyethyl b One or more of diol 4000), albumin, hydroxyethyl starch, sodium carboxymethylcellulose, hydroxypropyl- ⁇ -cyclodextrin, preferably in glycerol, polyethylene glycol and hydroxyethyl starch One or several, more preferably glycerin.
  • the sedimentation inhibitor mainly improves the stability of the system during storage and prevents the aggregation and precipitation of meloxicam particles.
  • the weight ratio of the meloxicam to the sedimentation inhibitor is from 1:0.1 to 1:100, preferably from 1:0.1 to 1:50, more preferably from 1:0.5 to 1:20, most preferably 1:0.5. 1:10.
  • the surface stabilizer may be a nonionic, anionic, cationic, and zwitterionic compound or surfactant such as polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropylmethylcellulose, Tween 80, poise One or more of Losham, 15-hydroxystearate polyethylene glycolate, lecithin, sodium deoxycholate, sodium cholate, sodium dodecyl sulfate, sodium lauryl sulfate.
  • nonionic, anionic, cationic, and zwitterionic compound or surfactant such as polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropylmethylcellulose, Tween 80, poise One or more of Losham, 15-hydroxystearate polyethylene glycolate, lecithin, sodium deoxycholate, sodium cholate, sodium dodecyl sulfate, sodium lauryl sulfate.
  • nonionic surface stabilizers include, but are not limited to, hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone, poloxamer, Tween-80, polyhydroxystearate hydroxystearate 15.
  • Useful anionic surface stabilizers include, but are not limited to, sodium dioctyl succinate (DOSS), sodium lauryl citrate, sodium dodecyl sulfate (SDS), sodium docusate, sodium cholate, and deoxycholic acid. sodium.
  • DOSS dioctyl succinate
  • SDS sodium dodecyl sulfate
  • sodium docusate sodium cholate
  • deoxycholic acid sodium.
  • Useful cationic surface stabilizers include, but are not limited to, polymers, biopolymers, poly-N-methylpyridinium, pyridinium sulfate, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polyphenylene Ethylene, polymethyl methacrylate trimethylammonium bromide (PMMTMABr), hexylmethyltrimethylammonium bromide (HDMAB) and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate .
  • Useful zwitterionic surface stabilizers include, but are not limited to, proteins, phospholipids, zwitterionic polymers, and zwitterionic surfactant molecules, such as phosphatidylcholine, lecithin, gelatin, and the like.
  • the surface stabilizer does not contain glycerin.
  • the weight ratio of the meloxicam to the surface stabilizer may be 1:0.01 to 1:100, preferably 1:0.01 to 1:50, more preferably 1:0.05 to 1:5, most preferably 1: 0.1 to 1:1.
  • the surface stabilizer comprises a first surface stabilizer and a second surface stabilizer, wherein the first surface stabilizer may be a nonionic or zwitterionic surface stabilizer, and may be selected from the group consisting of polyvinylpyrrolidone , polyvinyl alcohol, Tween 80, poloxamer, 15-hydroxystearic acid polyethylene glycol ester, lecithin, etc., preferably polyvinylpyrrolidone, poloxamer, Tween 80; second surface stabilizer can It is an anionic surface stabilizer and may be selected from sodium deoxycholate, sodium cholate, sodium dodecyl sulfate, sodium lauryl sulfate, etc., preferably sodium deoxycholate and sodium cholate.
  • first surface stabilizer may be a nonionic or zwitterionic surface stabilizer, and may be selected from the group consisting of polyvinylpyrrolidone , polyvinyl alcohol, Tween 80, poloxamer, 15-hydroxy
  • the weight ratio of meloxicam to the first surface stabilizer may be from 1:0.01 to 1:100, preferably from 1:0.01 to 1:50, more preferably from 1:0.05 to 1:5, most preferably 1: 0.1 to 1:1.
  • the weight ratio of meloxicam to the second surface stabilizer may be from 1:0.01 to 1:100, preferably from 1:0.01 to 1:50, more preferably from 1:0.01 to 1:5, most preferably 1: 0.01 to 1:1.
  • a preferred combination comprises a first surface stabilizer selected from the group consisting of polyvinylpyrrolidone, a second surface stabilizer selected from the group consisting of sodium deoxycholate, and a sedimentation inhibitor selected from the group consisting of glycerin, polyethylene glycol, and hydroxyethyl b.
  • a first surface stabilizer selected from the group consisting of polyvinylpyrrolidone
  • a second surface stabilizer selected from the group consisting of sodium deoxycholate
  • a sedimentation inhibitor selected from the group consisting of glycerin, polyethylene glycol, and hydroxyethyl b.
  • One or more of the base starches preferably glycerin.
  • the meloxicam nanoparticles of the present invention have an average particle size of less than 2000 nm, such as less than 1500 nm, preferably less than 1000 nm, more preferably less than 500 nm, and most preferably less than 200 nm.
  • the injectable pharmaceutical compositions of the present invention may further comprise a liquid medium selected from the group consisting of water, saline solutions, vegetable oils (such as safflower seed oil), and organic solvents (e.g., ethanol, tert-butanol, hexane, and Ethylene glycol) or the like is preferably water.
  • a liquid medium selected from the group consisting of water, saline solutions, vegetable oils (such as safflower seed oil), and organic solvents (e.g., ethanol, tert-butanol, hexane, and Ethylene glycol) or the like is preferably water.
  • the meloxicam is present in an amount of 10 to 100 mg/mL, preferably 10 to 50 mg/mL, more preferably 15 to 35 mg/mL, and most preferably 25 mg/mL.
  • the sedimentation inhibitor content may be from 0.1 to 100 mg/mL, preferably from 0.1 to 50 mg/mL, more preferably from 1 to 20 mg/mL.
  • the content of the first surface stabilizer is 0.1 to 100 mg/mL, preferably 1 to 50 mg/mL, more preferably 1 to 20 mg/mL; and the content of the second surface stabilizer is 0.1 to 100 mg. /mL, preferably 1 to 50 mg/mL, more preferably 1 to 10 mg/mL.
  • the present invention provides an injectable pharmaceutical composition
  • an injectable pharmaceutical composition comprising: (1) meloxicam nanoparticles, (2) polyvinylpyrrolidone, (3) sodium deoxycholate, (4) a sedimentation inhibitor And (5) water,
  • the sedimentation inhibitor is selected from one or more of glycerin, polyethylene glycol, hydroxyethyl starch, preferably glycerol; the average particle size of the meloxicam nanoparticles is less than 500 nm, preferably less than 200 nm;
  • the weight ratio of the meloxicam to the sedimentation inhibitor is 1:0.5 to 1:20, preferably 1:0.5 to 1:10;
  • the weight ratio of the meloxicam to the polyvinylpyrrolidone is 1:0.05 ⁇ 1:5, preferably 1:0.1 to 1:1;
  • the weight ratio of meloxicam to sodium deoxycholate is 1:0.05 to 1:5, preferably 1:0.1 to 1:1.
  • Another aspect of the present invention provides a method for preparing a meloxicam injectable pharmaceutical composition, comprising:
  • Grinding devices suitable for use in the present invention include dispersion mills such as ball mills, attritors, vibratory mills, and media mills such as sand mills and bead mills. These dispersion mills are well known in the art.
  • the nanoparticle preparation is a suspension liquid, which is a thermodynamically unstable system in the long term. Oswald ripening occurs during storage and aggregation and sedimentation occur, which hinders the clinical application of nanoparticle preparations.
  • the invention can increase the density or viscosity of the solution by adding a sedimentation inhibitor such as glycerin to the composition, inhibit the sedimentation of the meloxicam granule, thereby improving the stability of the meloxicam nanoparticle during long-term storage, and advancing it. In clinical application.
  • average particle diameter of less than 2000 nm means that at least 50% of the active material particles have an average particle diameter of less than about 2000 nm by weight.
  • the average particle size of the particles of the present invention can be measured by conventional particle size measurement techniques well known to those skilled in the art. Such techniques include, for example, settled field flow grading, photon correlation spectroscopy, light scattering, and the like.
  • the "weight to volume ratio" as used herein means the weight (in g) of the component per 100 mL of liquid system, i.e., g/100 mL.
  • the "D10” in the present invention means a particle diameter corresponding to a cumulative particle size distribution percentage of a sample of 10%.
  • “D50” refers to the particle size corresponding to a cumulative particle size distribution percentage of a sample of 50%.
  • D90 refers to the particle size corresponding to a cumulative particle size distribution percentage of a sample of 90%.
  • Optional or “optionally” means that the subsequently described event or environment may, but need not, occur, including where the event or environment occurs or does not occur.
  • optionally comprising a sedimentation inhibitor means that a sedimentation inhibitor may, but need not, be present, the description including the case of including a sedimentation inhibitor and the case of not including a sedimentation inhibitor.
  • the method for detecting insoluble particles of nanoparticle injection in the following examples is determined by microscopic method under the general rule of USP ⁇ 788>, and the particles containing 10 ⁇ m or more in each test container shall not exceed 3000 particles, and particles containing 25 ⁇ m or more. No more than 300 tablets.
  • the impurity content in the nanoparticle injection was detected by HPLC, and the detection conditions were ODS-2 column (5 ⁇ m, 4.6 ⁇ 150 mm), mobile phase: methanol/water, detection wavelengths: 260 nm and 350 nm.
  • Polyvinylpyrrolidone is used as the first surface stabilizer
  • sodium deoxycholate is the second surface stabilizer
  • glycerin is used as the sedimentation inhibitor to prepare the nanoparticle injection.
  • the specific composition and dosage are as follows:
  • PVP-K17 is used as the first surface stabilizer
  • sodium cholate is the second surface stabilizer
  • glycerin is used as the sedimentation inhibitor to prepare the nanoparticle injection.
  • the specific prescription composition and dosage are as follows:
  • the ability of different sedimentation inhibitors to inhibit sedimentation of the nanoparticle composition was examined by observing the appearance.
  • the nanoparticle compositions used contained 2.5% meloxicam, 0.5% PVP-K17 and 0.25% sodium deoxycholate and different types and amounts of sedimentation inhibitors by weight and volume ratio (see Table 7 for details).
  • the nanoparticle injection solution was prepared by the same preparation method as in Example 1, and the test results are shown in Table 7 below.
  • the effects of different types of sedimentation inhibitors were examined by detecting insoluble particles in the sample.
  • the nanoparticle compositions used contained 2.5% meloxicam, 0.5% PVP-K17 and 0.25% sodium deoxycholate and different types and amounts of sedimentation inhibitors by weight to volume ratio (see Table 8 for details).
  • the results of the detection of insoluble fine particles placed at 40 ° C for 15 d and 1 M are shown in Table 8 below.
  • the effects of different sedimentation inhibitors on product stability were investigated.
  • the nanoparticle compositions used contained 2.5% meloxicam, 0.5% PVP-K17 and 0.25% sodium deoxycholate and different types and amounts of sedimentation inhibitors by weight to volume ratio (see Table 9 for details).
  • the results of pH, particle size and insoluble particle detection at 40 ° C and 60 ° C for 10 d are shown in Table 9 below.
  • the mixture was placed at room temperature at 25 ° C for 1 M, and the appearance results are shown in Table 10.
  • Example 1 The nanoparticle injection solution obtained in Example 1 was placed under conditions of (25 ° C ⁇ 2 ° C, RH 60 ⁇ 5%) and (2 to 8 ° C) for 6 months to test the stability of the sample. The results are shown in Table 11. 12 is shown.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种包含美洛昔康的可注射的药物组合物及其制备方法，该药物组合物包含美洛昔康纳米颗粒、表面稳定剂和沉降抑制剂，其稳定性好，不易发生沉降，适于工业化大生产。

Description

一种包含美洛昔康的可注射的药物组合物及其制备方法 技术领域
本发明涉及药物制剂领域，具体涉及一种包含美洛昔康的可注射的药物组合物及其制备方法。
背景技术
美洛昔康是一种高效的非甾体类抗炎药，用于治疗类风湿性关节炎、骨关节炎和术后疼痛。美洛昔康选择性地抑制COX-2同工酶，具有高效抗炎和止痛的效果，且具有较低的胃肠道反应。目前上市的品种包括美洛昔康片、美洛昔康胶囊等口服剂型及美洛昔康注射液肌肉注射剂。口服剂型缺点在于：因原料润湿性差和溶解度低(pH 1.2和4.0，溶解度仅为0.6μg/mL)而导致吸收较慢，不能用于急性风湿、关节炎和疼痛。肌肉注射剂虽然改善了药物的吸收，但吸收速率依然受到原料药溶解度的限制，且还会造成局部组织疼痛。因此，增溶是改善美洛昔康体内药代动力学参数的关键。
提高美洛昔康溶解的方法有多种，如纳米晶、胶束、包合物、脂质体等，其中美洛昔康纳米晶具有明显的临床优势，其无需载体材料，仅需少量表面稳定剂，没有赋形剂带来的毒性问题(如溶血、过敏反应等)，不受包封率及载药量的制约，能够满足高剂量、高浓度制剂的的需求。与传统美洛昔康制剂相比，纳米晶的优势还体现在以下几个方面：
1)起效快，可用于急性疼痛的治疗。药物快速起效的关键是纳米尺寸的药物颗粒溶解度高、溶出速率快，达峰时间短，仅数十分钟，而传统制剂Tmax长达5-10h。
2)纳米晶技术明显提高了美洛昔康生物利用度，其AUC和Cmax分别是等剂量片剂的1.2倍和1.3倍。
3)扩大美洛昔康适应症。传统剂型主要用于类风湿性关节炎、疼痛性骨关节炎、强直性脊柱炎等，而美洛昔康静脉注射剂可用于术后急性疼痛的治疗。
4)不仅突破了传统制剂不能用于急性疼痛的局限，还保持了其长效的优势。传统制剂半衰期平均20h，而纳米晶药物虽为12h，但静脉注射15mg和60mg， 药效也可维持至24h。
5)与阿片类镇痛药相比，美洛昔康静脉注射剂可避免呼吸抑制、恶心呕吐、过度镇静、精神依赖等严重不良反应。同时，美洛昔康作为COX-2选择性抑制剂，与其他非甾体抗炎药相比，具有较小的不良反应。
6)降低消化道溃疡等不良反应。此外，口服制剂还会引起严重的胃肠道反应，发生率约1.9％-7.8％。纳米晶药物注射后被巨噬细胞吞噬，富集在肝脏、脾脏、肺组织，避免游离药物与胃肠道、血小板等正常组织上COX受体的结合，从而降低传统制剂存在的副作用。
纳米晶是一种固体颗粒在纳米级别的混悬液，是一种热力学不稳定体系，易产生沉降，导致注射液无法使用。CN101175481A公开了一种可注射的他克莫司纳米颗粒制剂中加入至少一种表面稳定剂，使得组合物当分散在生物相关介质中基本上保持纳米颗粒粒度，很少聚集。
US9345665公开了一种美洛昔康纳米颗粒注射液，其包含纳米级的美洛昔康颗粒、表面表面稳定剂，以及糖或缓冲剂等，能够减轻纳米颗粒注射液中产生的沉降，但是注射液在放置1到3个月后仍然会存在部分不溶性微粒，影响注射液的稳定性。
因此，开发可用于临床使用且质量稳定的美洛昔康纳米颗粒注射液是非常必要的。
发明内容
本发明一方面提供了一种稳定的美洛昔康纳米颗粒注射液，具体地说，本发明提供了一种可注射的药物组合物，包含美洛昔康纳米颗粒和表面稳定剂，所述药物组合物还包含沉降抑制剂。
其中，所述的沉降抑制剂可以选自多元醇或高分子聚合物，如甘油、丙二醇、聚乙二醇(例如聚乙二醇300、聚乙二醇400、聚乙二醇600、聚乙二醇4000)、白蛋白、羟乙基淀粉、羧甲基纤维素钠、羟丙基-β-环糊精中的一种或几种，优选甘油、聚乙二醇和羟乙基淀粉中的一种或几种，更优选甘油。沉降抑制剂主要在储藏过程中提高体系的稳定性，防止美洛昔康颗粒发生聚集和沉淀。
所述的美洛昔康与所述沉降抑制剂的重量比为1:0.1～1:100，优选 1:0.1～1:50，更优选1:0.5～1:20，最优选1:0.5～1:10。
在某些实施方式中，所述的表面稳定剂可以是非离子，阴离子，阳离子和两性离子化合物或表面活性剂，例如聚乙烯吡咯烷酮、聚乙烯醇、羟丙甲基纤维素、吐温80、泊洛沙姆、15-羟基硬脂酸聚乙二醇酯、卵磷脂、脱氧胆酸钠、胆酸钠、十二烷基磺酸钠、十二烷基硫酸钠中的一种或多种。
可用的非离子表面稳定剂包括但不限于羟丙基甲基纤维素(HPMC)、聚乙烯吡咯烷酮、泊洛沙姆、吐温-80、聚羟基硬脂酸羟基硬脂酸酯15。
可用的阴离子表面稳定剂包括但不限于二辛基琥珀酸钠(DOSS)、十二烷基璜酸钠、十二烷基硫酸钠(SDS)、多库酯钠、胆酸钠和脱氧胆酸钠。
可用的阳离子表面稳定剂包括但不限于聚合物、生物聚合物、聚-N-甲基吡啶鎓、硫酸吡啶鎓氯化物、阳离子磷脂、壳聚糖、聚赖氨酸、聚乙烯咪唑、聚苯乙烯、聚甲基丙烯酸甲酯三甲基溴化铵(PMMTMABr)、己基甲基三甲基溴化铵(HDMAB)和聚乙烯吡咯烷酮-2-二甲氨基乙基甲基丙烯酸二甲酯硫酸盐。
可用的两性离子表面稳定剂包括但不限于蛋白质、磷脂、两性离子聚合物和两性离子表面活性剂分子，例如可以是磷脂酰胆碱、卵磷脂、明胶等。
所述的表面稳定剂不包含甘油。
其中，所述美洛昔康与所述表面稳定剂的重量比可为1:0.01～1:100，优选1:0.01～1:50，更优选1:0.05～1:5，最优选1:0.1～1:1。
在某些优选的实施例中，所述的表面稳定剂包含第一表面稳定剂和第二表面稳定剂，其中第一表面稳定剂可以是非离子或两性离子表面稳定剂，可选自聚乙烯吡咯烷酮、聚乙烯醇、吐温80、泊洛沙姆、15-羟基硬脂酸聚乙二醇酯、卵磷脂等，优选聚乙烯吡咯烷酮、泊洛沙姆、吐温80；第二表面稳定剂可以是阴离子表面稳定剂，可选自脱氧胆酸钠、胆酸钠、十二烷基磺酸钠、十二烷基硫酸钠等，优选脱氧胆酸钠、胆酸钠。
其中，美洛昔康与所述第一表面稳定剂的重量比可为1:0.01～1:100，优选1:0.01～1:50，更优选1:0.05～1:5，最优选1:0.1～1:1。
其中，美洛昔康与所述第二表面稳定剂的重量比可为1:0.01～1:100，优选1:0.01～1:50，更优选1:0.01～1:5，最优选1:0.01～1:1。
在某些优选的实施例中，优选的组合包括第一表面稳定剂选自聚乙烯吡咯 烷酮，第二表面稳定剂选自脱氧胆酸钠，沉降抑制剂选自甘油、聚乙二醇、羟乙基淀粉中的一种或几种，优选甘油。
本发明所述的美洛昔康纳米颗粒的平均粒径小于2000nm，例如可以小于1500nm，优选小于1000nm，更优选小于500nm，最优选小于200nm。
本发明所述的可注射的药物组合物还可包含液体介质，所述液体介质选自水、盐水溶液、植物油(例如红花籽油)和有机溶剂(例如乙醇，叔丁醇，己烷和乙二醇)等，优选水。
在药物组合物中，所述的美洛昔康的含量为10～100mg/mL，优选10～50mg/mL，更优选15～35mg/mL，最优选25mg/mL。
在药物组合物中，所述沉降抑制剂含量可以是0.1～100mg/mL，优选0.1～50mg/mL，更优选1～20mg/mL。
在药物组合物中，所述第一表面稳定剂的含量为0.1～100mg/mL，优选1～50mg/mL，更优选1～20mg/mL；所述第二表面稳定剂的含量为0.1～100mg/mL，优选1～50mg/mL，更优选1～10mg/mL。
本发明另一方面还提供了一种可注射的药物组合物，包含：(1)美洛昔康纳米颗粒、(2)聚乙烯吡咯烷酮、(3)脱氧胆酸钠、(4)沉降抑制剂和(5)水，
其中，所述沉降抑制剂选自甘油、聚乙二醇、羟乙基淀粉中的一种或几种，优选甘油；所述美洛昔康纳米颗粒的平均粒径小于500nm，优选小于200nm；所述美洛昔康与所述沉降抑制剂的重量比为1:0.5～1:20，优选1:0.5～1:10；所述美洛昔康与聚乙烯吡咯烷酮的重量比为1:0.05～1:5，优选1:0.1～1:1；所述美洛昔康与脱氧胆酸钠的重量比为1:0.05～1:5，优选1:0.1～1:1。
本发明另一方面还提供了一种美洛昔康可注射的药物组合物的制备方法，包括：
1)将表面稳定剂、美洛昔康以及任选的沉降抑制剂混合；
2)将上述混合体系进行研磨制备分散体；以及任选地，
3)将沉降抑制剂与上述分散体混合。
适用于本发明的研磨装置包括诸如球磨机、磨碎机、振动研磨机等分散研磨机和诸如砂磨机和珠磨机等介质研磨机。这些分散研磨机在本领域中是众所周知的。
尽管在美洛昔康纳米颗粒注射组合物中加入表面稳定剂能够提高美洛昔康纳米颗粒在制备过程中的分散性，但纳米颗粒制剂为混悬型液体，为热力学不稳定体系，在长期的贮存过程中会发生奥斯瓦尔德熟化现象而发生聚集和沉降，这阻碍了纳米颗粒制剂在临床上的应用。本发明通过在组合物中加入甘油等沉降抑制剂，可以提高溶液的密度或者粘度，抑制美洛昔康颗粒发生沉降，从而提高美洛昔康纳米颗粒在长期贮存过程中的稳定性，推进其在临床上的应用。
在本申请的说明书和权利要求书中，除非另有说明，否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。然而，为了更好地理解本发明，下面提供了部分相关术语的定义和解释。
本发明中所述的例如“平均粒径小于2000nm”是指按重量计算，至少50％的活性物质颗粒的粒径平均值小于约2000nm。
本发明所述的颗粒的平均粒径可通过本领域技术人员熟知的常规粒度测量技术测量颗粒的平均粒径。这样的技术包括例如沉降场流分级，光子相关光谱，光散射等。
本发明所述的“重量体积比”是指每100mL液体体系中含有所述成分的重量(单位g)，即g/100mL。
本发明所述的“D10”是指一个样品的累计粒度分布百分数达到10％时所对应的粒径。“D50”是指一个样品的累计粒度分布百分数达到50％时所对应的粒径。“D90”是指一个样品的累计粒度分布百分数达到90％时所对应的粒径。
“任选”或“任选地”意味着随后所描述地事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生地场合。例如，“任选包含沉降抑制剂”意味着沉降抑制剂可以但不必须存在，该说明包括包含沉降抑制剂的情形和不包含沉降抑制剂的情形。
具体实施方式
通过以下实施例和实验例进一步详细说明本发明。这些实施例和实验例仅用于说明性目的，而并不用于限制本发明的范围。
以下实施例中纳米颗粒注射液不溶性微粒的检测方法参照USP<788>通则项下，显微技术法测定，每个供试品容器中含10μm及以上微粒不得超过3000粒，含25μm及以上微粒不得超过300粒。
纳米颗粒注射液中杂质含量通过HPLC检测，其检测条件为ODS-2柱(5μm，4.6×150mm)，流动相：甲醇/水，检测波长：260nm和350nm。
实施例1
以聚乙烯吡咯烷酮为第一表面稳定剂，脱氧胆酸钠为第二表面稳定剂，甘油作为沉降抑制剂，制备纳米颗粒注射液，具体处方组成及用量如下：
表1处方组成及用量
Figure PCTCN2018101924-appb-000001
制备方法：
1)将处方量的PVP-K17和脱氧胆酸钠溶解于总重50％的水中；
2)将美洛昔康原料加入上述体系中，混合均匀；
3)将上述混合体系加入填充有研磨珠的研磨机腔体中进行研磨6h；
4)将沉降抑制剂加入上述研磨液中，并定至目标重量。
考察上述纳米颗粒注射液的粒径、pH值、渗透压、不溶性微粒和有关物质等指标，检测结果如下：
表2粒径、pH值、渗透压、不溶性微粒检测结果
Figure PCTCN2018101924-appb-000002
表3有关物质检测结果
时间 最大单杂 总杂
起始 0.132％ 0.324％
40d_10D 0.164％ 0.367％
结果显示，以2.5％甘油作为沉降抑制剂制备的注射液渗透压合格，在加速40℃条件下放置一定的时间，pH值、粒径、不溶性微粒和有关物质无明显变化。说明样品的稳定性良好。
实施例2
以PVP-K17为第一表面稳定剂，胆酸钠为第二表面稳定剂，甘油作为沉降抑制剂，制备纳米颗粒注射液，具体处方组成及用量如下：
表4处方组成及用量
Figure PCTCN2018101924-appb-000003
制备方法：
1)将处方量的PVP-K17和胆酸钠溶解于总重50％的水中；
2)将美洛昔康原料加入上述体系中，混合均匀；
3)将上述混合体系加入填充有研磨珠的研磨机腔体中进行研磨8h；
4)将沉降抑制剂加入上述研磨液中，并定至目标重量。
考察上述纳米颗粒注射液的粒径、pH值、渗透压、不溶性微粒和有关物质等指标，检测结果如下：
表5粒径、pH值、渗透压、不溶性微粒检测结果
Figure PCTCN2018101924-appb-000004
表6有关物质检测结果
时间 最大单杂 总杂
起始 0.138％ 0.343％
40d 10天 0.152％ 0.328％
结果显示，以5％甘油作为沉降抑制剂制备的注射液渗透压符合规定，在加速40℃条件下放置一定的时间，pH值、粒径、不溶性微粒和有关物质无明显变化。说明样品的稳定性良好。
实施例3
通过观察外观考察不同沉降抑制剂抑制纳米颗粒组合物沉降的能力。所用的纳米颗粒组合物中均含有以重量体积比计的2.5％美洛昔康、0.5％PVP-K17和0.25％脱氧胆酸钠和不同种类和用量的沉降抑制剂(详见表7)，采用实施例 1相同的制备方法制备纳米颗粒注射液，检测结果如下表7。
表7不同沉降抑制剂对沉降的抑制作用
Figure PCTCN2018101924-appb-000005
结果显示，温度对产品稳定性有一定的影响，温度越高，体系越不稳定。此外，甘油相比其他沉降抑制剂具有更好的抑制析晶作用。
实施例4
通过检测样品中不溶性微粒来考察不同种类的沉降抑制剂的效果。所用的纳米颗粒组合物中均含有以重量体积比计的2.5％美洛昔康、0.5％PVP-K17和0.25％脱氧胆酸钠和不同种类和用量的沉降抑制剂(详见表8)。40℃放置15d和1M的不溶性微粒检测结果如下表8所示。
表8不同沉降抑制剂对产品不溶性微粒的影响
Figure PCTCN2018101924-appb-000006
结果显示，采用蔗糖、右旋糖酐40和磷酸盐缓冲液作为沉降抑制剂时，产品在加速条件下放置1M出现不溶性微粒增加和沉降现象，而以甘油作为沉降 抑制剂，不溶性微粒数较少，纳米颗粒体系稳定性良好。
实施例5
考察不同沉降抑制剂对产品稳定性的影响。所用的纳米颗粒组合物中均含有以重量体积比计的2.5％美洛昔康、0.5％PVP-K17和0.25％脱氧胆酸钠和不同种类和用量的沉降抑制剂(详见表9)。40℃和60℃放置10d的pH值、粒径和不溶性微粒检测结果如下表9所示。室温25℃放置1M，外观结果如表10所示。
表9pH值、粒径和不溶性微粒检测结果
Figure PCTCN2018101924-appb-000007
表10含不同沉降抑制剂的样品室温放置1M外观
沉降抑制剂 时间 外观
5％甘油 室温1M 淡黄色乳状液，无沉降，外观良好
2.5％甘油 室温1M 淡黄色乳状液，无沉降，外观良好
2.5％甘露醇 室温1M 淡黄色乳状液，有沉降，底部出现黄色片状固体
结果显示，1)以5％甘油、2.5％甘油和2.5％甘露醇作为沉降抑制剂在40℃和60℃条件下放置10d，pH值变化不大；2)40℃条件下放置10d，含5％甘油、2.5％甘油和2.5甘露醇的样品不溶性微粒变化不大，60℃条件下放置10d，含5％甘油和2.5％甘露醇的样品出现小幅增加趋势，但含2.5％甘油的样品无明显变化。3)室温放置1M，以2.5％甘露醇样品作为沉降抑制剂的样品底部出现片状析晶，而以甘油作为沉降抑制剂的样品外观良好。以甘油作为沉降抑制剂的产品相比2.5％甘露醇作为沉降抑制剂的产品的稳定性更好。
实施例6
将实施例1所得的纳米颗粒注射液分别于(25℃±2℃、RH60±5％)以及(2～8℃)的条件下放置6个月，测试样品的稳定性，结果如表11、12所示。
表11加速试验结果
Figure PCTCN2018101924-appb-000008
表12长期试验结果
Figure PCTCN2018101924-appb-000009
结果显示，样品在各条件下长时间放置，性状、pH、粒度、杂质含量等均无明显变化，稳定性良好。

Claims (13)

  1. 一种可注射的药物组合物，包含美洛昔康纳米颗粒和表面稳定剂，其特征在于，所述药物组合物还包含沉降抑制剂，其中所述的沉降抑制剂选自甘油、丙二醇、聚乙二醇、白蛋白、羟乙基淀粉、羧甲基纤维素钠、羟丙基-β-环糊精中的一种或几种，优选甘油、聚乙二醇和羟乙基淀粉中的一种或几种，更优选甘油。
  2. 根据权利要求1所述的药物组合物，其特征在于，所述的美洛昔康与所述沉降抑制剂的重量比为1:0.1～1:100，优选1:0.1～1:50，更优选1:0.5～1:20，最优选1:0.5～1:10。
  3. 根据权利要求1所述的药物组合物，其特征在于，所述的表面稳定剂选自聚乙烯吡咯烷酮、聚乙烯醇、羟丙甲基纤维素、吐温80、泊洛沙姆、15-羟基硬脂酸聚乙二醇酯、卵磷脂、脱氧胆酸钠、胆酸钠、十二烷基磺酸钠、十二烷基硫酸钠中的一种或多种。
  4. 根据权利要求1所述的药物组合物，其特征在于，所述美洛昔康与所述表面稳定剂的重量比可为1:0.01～1:100，优选1:0.01～1:50，更优选1:0.05～1:5，最优选1:0.1～1:1。
  5. 根据权利要求1所述的药物组合物，其特征在于，所述表面稳定剂不包含甘油。
  6. 根据权利要求1所述的药物组合物，其特征在于，所述的表面稳定剂包含第一表面稳定剂和第二表面稳定剂，其中第一表面稳定剂选自非离子或两性离子表面稳定剂，优选聚乙烯吡咯烷酮、聚乙烯醇、羟丙甲基纤维素、吐温80、泊洛沙姆、15-羟基硬脂酸聚乙二醇酯、卵磷脂等，更优选聚乙烯吡咯烷酮、泊洛沙姆、吐温80；第二表面稳定剂选自阴离子表面稳定剂，优选脱氧胆酸钠、胆酸钠、十二烷基磺酸钠、十二烷基硫酸钠，更优选脱氧胆酸钠、胆酸钠。
  7. 根据权利要求6所述的药物组合物，其特征在于，所述美洛昔康与所述第一表面稳定剂的重量比为1:0.01～1:100，优选1:0.01～1:50，更优选1:0.05～1:5，最优选1:0.1～1:1；所述美洛昔康与所述第二表面稳定剂的重量比为可为1:0.01～1:100，优选1:0.01～1:50，更优选1:0.01～1:5，最优选1:0.01～1:1。
  8. 根据权利要求1所述的药物组合物，其特征在于，所述的美洛昔康纳米 颗粒的平均粒径小于2000nm，优选小于1000nm，更优选小于500nm，最优选小于200nm。
  9. 根据权利要求1所述的药物组合物，其特征在于，所述的药物组合物还包含液体介质，所述液体介质选自水、盐水溶液、红花籽油、乙醇、叔丁醇、己烷和乙二醇，优选水。
  10. 根据权利要求9所述的药物组合物，其特征在于，以活性物质与药物组合物的重量体积比计算，所述的美洛昔康的含量为10～100mg/mL，优选10～50mg/mL，更优选15～35mg/mL，最优选25mg/mL。
  11. 一种可注射的药物组合物，包含：(1)美洛昔康纳米颗粒、(2)聚乙烯吡咯烷酮、(3)脱氧胆酸钠、(4)沉降抑制剂和(5)水，
    其中，所述沉降抑制剂选自甘油、聚乙二醇、羟乙基淀粉中的一种或几种，优选甘油；所述美洛昔康纳米颗粒的平均粒径小于500nm，优选小于200nm。
  12. 根据权利要求11所述的药物组合物，其特征在于，所述美洛昔康与所述沉降抑制剂的重量比为1:0.5～1:20，优选1:0.5～1:10；所述美洛昔康与聚乙烯吡咯烷酮的重量比为1:0.05～1:5，优选1:0.1～1:1；所述美洛昔康与脱氧胆酸钠的重量比为1:0.05～1:5，优选1:0.1～1:1。
  13. 一种制备如权利要求1～12所述的可注射的药物组合物的制备方法，包括：
    1)将表面稳定剂、美洛昔康以及任选的沉降抑制剂混合；
    2)将上述混合体系进行研磨制备分散体；以及任选地，
    3)将沉降抑制剂与上述分散体混合。
PCT/CN2018/101924 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法 Ceased WO2019037757A1 (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020207004076A KR20200046018A (ko) 2017-08-24 2018-08-23 멜록시캄을 함유하는 주사용 약학 조성물 및 그 제조 방법
AU2018321744A AU2018321744A1 (en) 2017-08-24 2018-08-23 Injectable pharmaceutical composition containing meloxicam, and preparation method therefor
JP2020508401A JP2020531424A (ja) 2017-08-24 2018-08-23 メロキシカムを含有する注射用医薬組成物、およびその製造方法
US16/638,842 US20200360268A1 (en) 2017-08-24 2018-08-23 Injectable pharmaceutical composition containing meloxicam, and preparation method therefor
EP18849101.3A EP3673897A4 (en) 2017-08-24 2018-08-23 INJECTABLE PHARMACEUTICAL COMPOSITION WITH MELOXICAM AND METHOD FOR MANUFACTURING IT
CA3070251A CA3070251A1 (en) 2017-08-24 2018-08-23 Injectable pharmaceutical composition containing meloxicam, and preparation method therefor
BR112020001907-0A BR112020001907A2 (pt) 2017-08-24 2018-08-23 composição farmacêutica injetável contendo meloxicam, e seu método de preparação
RU2020108079A RU2020108079A (ru) 2017-08-24 2018-08-23 Инъекционная фармацевтическая композиция, содержащая мелоксикам, и способ ее получения
CN202111036633.4A CN113925830B (zh) 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法
CN201880004385.5A CN109963555B (zh) 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710733082.4 2017-08-24
CN201710733082 2017-08-24

Publications (1)

Publication Number Publication Date
WO2019037757A1 true WO2019037757A1 (zh) 2019-02-28

Family

ID=65438429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/101924 Ceased WO2019037757A1 (zh) 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法

Country Status (11)

Country Link
US (1) US20200360268A1 (zh)
EP (1) EP3673897A4 (zh)
JP (1) JP2020531424A (zh)
KR (1) KR20200046018A (zh)
CN (2) CN109963555B (zh)
AU (1) AU2018321744A1 (zh)
BR (1) BR112020001907A2 (zh)
CA (1) CA3070251A1 (zh)
RU (1) RU2020108079A (zh)
TW (1) TW201912148A (zh)
WO (1) WO2019037757A1 (zh)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823787A (zh) * 2019-11-21 2021-05-21 北京泰德制药股份有限公司 一种含有美洛昔康的注射液及其制备方法
US11040008B2 (en) 2018-04-04 2021-06-22 Slayback Pharma Llc Pharmaceutical compositions of meloxicam
CN113440529A (zh) * 2020-03-25 2021-09-28 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN116407497A (zh) * 2021-12-30 2023-07-11 瑞普（天津）生物药业有限公司 一种复方阿法沙龙注射液及其制备方法
WO2024198768A1 (zh) * 2023-03-24 2024-10-03 珠海贝海生物技术有限公司 一种美洛昔康组合物及其制备方法和应用
US12263176B2 (en) 2020-07-06 2025-04-01 Slayback Pharma Llc Pharmaceutical liquid compositions of meloxicam
WO2025140464A1 (zh) * 2023-12-29 2025-07-03 广东东阳光药业股份有限公司 一种非甾体抗炎药的组合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021059234A1 (en) * 2019-09-26 2021-04-01 Cadila Healthcare Limited Stable aqueous parenteral solutions of nonsteroidal anti-inflammatory drugs (nsaids)
CN112587497A (zh) * 2020-12-25 2021-04-02 苏州中化药品工业有限公司 一种美洛昔康混悬液胶囊剂及其制备方法
US20240216387A1 (en) * 2021-04-27 2024-07-04 Animuscure Inc. Composition for preventing or treating muscular disease, comprising oxicam-based compound
EP4395765A4 (en) * 2021-08-31 2025-07-02 Natsar Pharmaceuticals Inc INTRAVENOUS FORMULATIONS OF RK-33
CN116327711B (zh) * 2022-01-18 2026-01-23 中国人民解放军军事科学院军事医学研究院 一种生物利用度高的美洛昔康纳米晶组合物及其应用
CN114504553B (zh) * 2022-02-28 2023-06-06 沈阳信达泰康医药科技有限公司 一种含有卵磷脂的美洛昔康的纳米分散体系
CN114569553B (zh) * 2022-02-28 2023-06-09 沈阳信达泰康医药科技有限公司 一种不含高分子稳定剂的美洛昔康纳米分散体系
CN114796133B (zh) * 2022-05-31 2023-08-25 浙江萃泽医药科技有限公司 一种注射用药物制剂及其制备方法
CN115300515A (zh) * 2022-08-11 2022-11-08 南京红地生物科技有限公司 一种含有美洛昔康和盐酸曲马多的长效注射液
CN116172990B (zh) * 2022-09-29 2024-03-08 中国人民解放军军事科学院军事医学研究院 一种姜黄素纳米晶药物组合物及其制备方法和其应用
CN115844820B (zh) * 2022-11-23 2023-08-29 石家庄四药有限公司 一种美洛昔康混悬注射液及其制备方法
CN116196273B (zh) * 2023-03-31 2025-04-29 江苏慧聚药业股份有限公司 一种美洛昔康注射液及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101175481A (zh) 2005-03-17 2008-05-07 伊兰制药国际有限公司 纳米颗粒免疫抑制化合物的可注射的组合物
CN103690480A (zh) * 2013-12-18 2014-04-02 吉林修正药业新药开发有限公司 治疗类风湿性关节炎、骨性关节炎的美洛昔康注射液及其制备方法
US9345665B2 (en) 2009-05-27 2016-05-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
US20170157061A1 (en) * 2003-03-03 2017-06-08 Recro Gainesville Llc Nanoparticulate Meloxicam Formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
DE10030345A1 (de) * 2000-06-20 2002-01-10 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
EP1938803A3 (en) * 2003-03-03 2010-10-27 Elan Pharma International Limited Formulations comprising nanoparticulate meloxican
PT1824493E (pt) * 2004-12-06 2008-11-18 Janssen Pharmaceutica Nv Suspensão oral que compreende meloxicam
CA2645205C (en) * 2006-05-19 2012-12-04 Norbrook Laboratories Limited Stable aqueous suspension having palatable taste
GB2438287A (en) * 2006-05-19 2007-11-21 Norbrook Lab Ltd Stable aqueous suspension
SG175768A1 (en) * 2009-04-24 2011-12-29 Iceutica Pty Ltd A novel formulation of meloxicam

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170157061A1 (en) * 2003-03-03 2017-06-08 Recro Gainesville Llc Nanoparticulate Meloxicam Formulations
CN101175481A (zh) 2005-03-17 2008-05-07 伊兰制药国际有限公司 纳米颗粒免疫抑制化合物的可注射的组合物
US9345665B2 (en) 2009-05-27 2016-05-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
CN103690480A (zh) * 2013-12-18 2014-04-02 吉林修正药业新药开发有限公司 治疗类风湿性关节炎、骨性关节炎的美洛昔康注射液及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LI, JIANHE ET AL.: "Advances in Research, Development and Clinical Application of Meloxicam Preparation", CHINA PHARMACY, vol. 24, no. 02, 31 January 2013 (2013-01-31), pages 162 - 167, XP009519443, ISSN: 1001-0408 *
QIAN, SHUAI ET AL.: "Research Progress in Nanosuspensions", PROGRESS IN PHARMACEUTICAL SCIENCES, vol. 31, no. 01, 31 January 2007 (2007-01-31), pages 9 - 14, XP009519444, ISSN: 1001-5094 *
See also references of EP3673897A4
WEI CHAO, HOU FEIYAN: "Passage; Pharmaceutics", PHARMACEUTICS, 31 August 2012 (2012-08-31), pages 122 - 125, XP009519435, ISBN: 978-7-5349-5936-3 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040008B2 (en) 2018-04-04 2021-06-22 Slayback Pharma Llc Pharmaceutical compositions of meloxicam
CN112823787A (zh) * 2019-11-21 2021-05-21 北京泰德制药股份有限公司 一种含有美洛昔康的注射液及其制备方法
CN112823787B (zh) * 2019-11-21 2023-02-21 北京泰德制药股份有限公司 一种含有美洛昔康的注射液及其制备方法
CN113440529A (zh) * 2020-03-25 2021-09-28 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
US12263176B2 (en) 2020-07-06 2025-04-01 Slayback Pharma Llc Pharmaceutical liquid compositions of meloxicam
CN116407497A (zh) * 2021-12-30 2023-07-11 瑞普（天津）生物药业有限公司 一种复方阿法沙龙注射液及其制备方法
CN116407497B (zh) * 2021-12-30 2026-05-12 瑞普（天津）生物药业有限公司 一种复方阿法沙龙注射液及其制备方法
WO2024198768A1 (zh) * 2023-03-24 2024-10-03 珠海贝海生物技术有限公司 一种美洛昔康组合物及其制备方法和应用
WO2025140464A1 (zh) * 2023-12-29 2025-07-03 广东东阳光药业股份有限公司 一种非甾体抗炎药的组合物

Also Published As

Publication number Publication date
KR20200046018A (ko) 2020-05-06
CN109963555B (zh) 2021-10-08
CA3070251A1 (en) 2019-02-28
EP3673897A4 (en) 2021-05-05
JP2020531424A (ja) 2020-11-05
TW201912148A (zh) 2019-04-01
BR112020001907A2 (pt) 2020-08-04
CN109963555A (zh) 2019-07-02
AU2018321744A1 (en) 2020-04-02
US20200360268A1 (en) 2020-11-19
RU2020108079A (ru) 2021-09-24
CN113925830A (zh) 2022-01-14
EP3673897A1 (en) 2020-07-01
CN113925830B (zh) 2023-07-14
RU2020108079A3 (zh) 2021-11-22

Similar Documents

Publication Publication Date Title
CN109963555B (zh) 一种包含美洛昔康的可注射的药物组合物及其制备方法
Jacob et al. Emerging role of nanosuspensions in drug delivery systems
Nasr et al. In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting
CN102256597A (zh) 制备含有不溶性药物的纳米颗粒的粉末的方法、由此制备的粉末以及含有该粉末的药物组合物
CA2492488A1 (en) Liquid dosage compositions of stable nanoparticulate active agents
EP2416782A1 (en) Controlled-release clozapine compositions
KR20080002689A (ko) 세팔로스포린을 함유하는 나노미립자 및 조절 방출 조성물
JP5848326B2 (ja) ペクチン−アドリアマイシン共役体の凍結乾燥製剤および製造方法
CN103097379A (zh) 纳米结构的阿瑞匹坦组合物、其制备方法以及包含其的药物组合物
CN110151691A (zh) 一种千金藤素纳米混悬液及其制备方法
Raula et al. Coated particle assemblies for the concomitant pulmonary administration of budesonide and salbutamol sulphate
WO2020034989A1 (zh) 一种可注射的药物组合物及其制备方法
Al Hazzaa et al. Cilnidipine nanocrystals, formulation and evaluation for optimization of solubility and dissolution rate
CN110711176A (zh) 一种西尼地平纳米混悬液及其制备方法
Al-Gharani et al. Formulation and in vitro Evaluation of Acemetacin Nanosuspension
CN104511020A (zh) 一种紫杉醇的药物组合物
Pardhi et al. Strategic Nanosuspension of Darolutamide for Enhanced Dissolution, Bioavailability, and Potentiated Prostate Cancer Treatment: Insights from Multiscale Computational Modeling
CN107441048A (zh) 一种阿利沙坦酯药物组合物及含有该药物组合物的制剂及其制备方法
HK40009384B (zh) 一种包含美洛昔康的可注射的药物组合物及其制备方法
EP3110400A1 (en) Nanostructured composition comprising indomethacine, its pharmaceutically acceptable salts and co-crystals and process for the preparation thereof
CN116350592A (zh) 一种司替戊醇纳米晶及其制备方法与应用
Hussien Preparation and evaluation of oral microsponge drug delivery system of ketoconazole
WO2021201800A1 (en) Flurbiprofen nanosuspension based gel formulation
HK40009384A (zh) 一种包含美洛昔康的可注射的药物组合物及其制备方法
CN104511022A (zh) 一种紫杉醇的药物组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18849101

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3070251

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020001907

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020508401

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018849101

Country of ref document: EP

Effective date: 20200324

ENP Entry into the national phase

Ref document number: 2018321744

Country of ref document: AU

Date of ref document: 20180823

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112020001907

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200129